NEW YORK (GenomeWeb News) – Lucigen said on Tuesday that it has received ISO 13485 certification, achieving a major step required to submit a diagnostic test to the US Food and Drug Administration.

The ISO 13485 standard covers medical device and diagnostic product development and manufacturing, and certification was provided by the British Standards Institution-USA. Lucigen said that it plans to enter clinical trials in late 2014 and to release its first molecular diagnostic test in 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.